单位：人民币百万元

<table>
  <tr>
    <th>产业链位置</th>
    <th>公司名称</th>
    <th>代码</th>
    <th>医美产品</th>
    <th>上市时间</th>
    <th>营业收入</th>
    <th>净利润</th>
    <th>毛利率</th>
    <th>净利率</th>
    <th>市值</th>
    <th>市盈率</th>
  </tr>
  <tr>
    <td rowspan="4">上游</td>
    <td>原材料及产品提供商</td>
    <td>华熙生物</td>
    <td>688363.CH</td>
    <td>透明质酸及“润百颜”注射用玻尿酸</td>
    <td>06/11/2019</td>
    <td>1,263 1,886 1,596</td>
    <td>424 586 437</td>
    <td>80% 80% 81%</td>
    <td>34% 31% 27%</td>
    <td>2018年12月28日 2019年12月31日 2020年6月30日</td>
    <td>40,032 70,992</td>
    <td>68 73</td>
  </tr>
  <tr>
    <td>原材料及产品提供商</td>
    <td>昊海生科</td>
    <td>6826.HK/688366.CH</td>
    <td>透明质酸及“海薇”注射用玻尿酸</td>
    <td>30/04/2015</td>
    <td>1,546 1,595 887</td>
    <td>415 371 102</td>
    <td>79% 77% 77%</td>
    <td>27% 23% 12%</td>
    <td>5,880 14,021 13,779</td>
    <td>14 38 44</td>
  </tr>
  <tr>
    <td>原材料及产品提供商</td>
    <td>爱美客</td>
    <td>300896.CH</td>
    <td>透明质酸</td>
    <td>28/09/2020</td>
    <td>321 558 464</td>
    <td>123 306 286</td>
    <td>89% 93% 92%</td>
    <td>38% 55% 62%</td>
    <td></td>
    <td>69</td>
  </tr>
  <tr>
    <td>原材料及产品提供商</td>
    <td>科研生物</td>
    <td>1786.TT</td>
    <td>透明质酸及“法思丽”注射用玻尿酸</td>
    <td>29/12/2010</td>
    <td>76 102 72</td>
    <td>22 31 19</td>
    <td>66% 70%</td>
    <td>28% 31% 26%</td>
    <td>924 1,020 924</td>
    <td>43 33 111</td>
  </tr>
  <tr>
    <td>原材料提供商</td>
    <td>阜丰集团</td>
    <td>SEHK:546</td>
    <td>透明质酸</td>
    <td>08/02/2007</td>
    <td>13,909 16,346 16,636</td>
    <td>1,845 1,137 904</td>
    <td>19% 20% 19%</td>
    <td>13% 7% 5%</td>
    <td>6,601 7,891 5,696</td>
    <td>4 7 3</td>
  </tr>
  <tr>
    <td>产品提供商</td>
    <td>双鹭药业</td>
    <td>002038.CH</td>
    <td>子公司生产“舒颜”注射用玻尿酸</td>
    <td>27/01/2005</td>
    <td>2,167 2,030 842</td>
    <td>571 487 302</td>
    <td>79% 79% 85%</td>
    <td>26% 24% 36%</td>
    <td>25,480 13,505 13,156</td>
    <td>45 28 20</td>
  </tr>
  <tr>
    <td>产品提供商</td>
    <td>冠昊生物</td>
    <td>300238.CH</td>
    <td>丰膜组织胶</td>
    <td>06/07/2011</td>
    <td>458 438 319</td>
    <td>46 (465) 36</td>
    <td>73% 68% 73%</td>
    <td>10% -106% 11%</td>
    <td>2,528 5,064 4,720</td>
    <td>55 (11) 92</td>
  </tr>
  <tr>
    <td>医美机构</td>
    <td>朗姿股份</td>
    <td>002612.CH</td>
    <td>持股韩国整形美容集团</td>
    <td>30/08/2011</td>
    <td>2,662 3,007 1,997</td>
    <td>210 59 48</td>
    <td>58% 58% 54%</td>
    <td>8% 2% 2%</td>
    <td>3,881 4,296 4,500</td>
    <td>18 73 41</td>
  </tr>
  <tr>
    <td>医美机构</td>
    <td>鹏爱医疗国际</td>
    <td>Nasdaq GM:AIH</td>
    <td>连锁医美机构</td>
    <td>25/10/2019</td>
    <td>761 869 777</td>
    <td>(255) 136 (216)</td>
    <td>66% 68% 61%</td>
    <td>-34% 16% -28%</td>
    <td>1,055 1,030</td>
    <td>- 8 (2)</td>
  </tr>
  <tr>
    <td>医美机构</td>
    <td>华韩整形</td>
    <td>430335.OC</td>
    <td>连锁医美机构</td>
    <td>06/11/2013</td>
    <td>693 804</td>
    <td>4 83</td>
    <td>51% 51%</td>
    <td>1% 10%</td>
    <td>445 1,002 1,440</td>
    <td>125 12</td>
  </tr>
  <tr>
    <td>医美机构</td>
    <td>利美康</td>
    <td>832533.OC</td>
    <td>连锁医美机构</td>
    <td>04/06/2015</td>
    <td>315 153</td>
    <td>(15) (69)</td>
    <td>51% 33%</td>
    <td>-5% -45%</td>
    <td>402 321 174</td>
    <td>(27) (5)</td>
  </tr>
  <tr>
    <td>医美机构</td>
    <td>瑞澜医美(已退市)</td>
    <td>838265.OC</td>
    <td>连锁医美机构</td>
    <td>26/08/2016</td>
    <td>70</td>
    <td>(13)</td>
    <td>50%</td>
    <td>-19%</td>
    <td></td>
    <td></td>
  </tr>
  <tr>
    <td>医美电商平台</td>
    <td>新氧</td>
    <td>SY.US</td>
    <td>线上医美服务</td>
    <td>02/05/2019</td>
    <td>617 1,152 870</td>
    <td>55 177 (33)</td>
    <td>85% 83% 83%</td>
    <td>9% 15% -4%</td>
    <td>6,071 7,199</td>
    <td>34 (20)</td>
  </tr>
</table>

资料来源：Capital IQ、Wind数据库